Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mukesh Harisinghani

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|October 8, 2025
Benefits of Using cT1 for Risk Stratification in MASLDMukesh Harisinghani
The Lancet. Oncology|September 2, 2008
Nanoparticle-enhanced MRI: are we there yet?Mukesh Harisinghani
Hepatology (Baltimore, Md.)|November 8, 2023
Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver diseaseNaim Alkhouri, Mukesh Harisinghani
Hematology/Oncology Clinics of North America|July 25, 2006
New clinical imaging modalities in prostate cancerRobert Ross, Mukesh Harisinghani
AJR. American Journal of Roentgenology|April 4, 2013
Reply: To PMID 22623539Sadhna Verma, Mukesh Harisinghani
Radiologic Clinics of North America|October 13, 2006
Prostate cancer imaging--what the urologic oncologist needs to knowRobert Ross, Mukesh Harisinghani
Magma (New York, N.Y.)|May 20, 2022
PI-RADS: multiparametric MRI in prostate cancerAileen O'Shea, Mukesh Harisinghani
AJR. American Journal of Roentgenology|May 23, 2015
Metrics for Original Research Articles in the AJR: From First Submission to Final PublicationAndrew B Rosenkrantz, Mukesh Harisinghani
Abdominal Radiology (New York)|September 14, 2019
Introduction to the special section on rectal cancerMarc J Gollub, Mukesh Harisinghani
The Journal of Urology|August 12, 2005
Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancerShahin Tabatabaei, Mukesh Harisinghani, W Scott McDougal
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Liver International : Official Journal of the International Association for the Study of the Liver|October 8, 2025
Benefits of Using cT1 for Risk Stratification in MASLDMukesh Harisinghani
The Lancet. Oncology|September 2, 2008
Nanoparticle-enhanced MRI: are we there yet?Mukesh Harisinghani
Hepatology (Baltimore, Md.)|November 8, 2023
Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver diseaseNaim Alkhouri, Mukesh Harisinghani
Hematology/Oncology Clinics of North America|July 25, 2006
New clinical imaging modalities in prostate cancerRobert Ross, Mukesh Harisinghani
AJR. American Journal of Roentgenology|April 4, 2013
Reply: To PMID 22623539Sadhna Verma, Mukesh Harisinghani
Radiologic Clinics of North America|October 13, 2006
Prostate cancer imaging--what the urologic oncologist needs to knowRobert Ross, Mukesh Harisinghani
Magma (New York, N.Y.)|May 20, 2022
PI-RADS: multiparametric MRI in prostate cancerAileen O'Shea, Mukesh Harisinghani
AJR. American Journal of Roentgenology|May 23, 2015
Metrics for Original Research Articles in the AJR: From First Submission to Final PublicationAndrew B Rosenkrantz, Mukesh Harisinghani
Abdominal Radiology (New York)|September 14, 2019
Introduction to the special section on rectal cancerMarc J Gollub, Mukesh Harisinghani
The Journal of Urology|August 12, 2005
Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancerShahin Tabatabaei, Mukesh Harisinghani, W Scott McDougal
Pageof 12